Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ANI Pharma Expands Sofgen Development Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

ANI Pharma Expands Sofgen Development Pact

Sofgen to develop, manufacture generic soft gel drug product

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ANI Pharmaceuticals, Inc. has signed an exclusive licensing, development and supply agreement with Sofgen Pharmaceuticals for an undisclosed ANDA soft gel oral drug product. Sofgen will provide development, manufacture and regulatory submission of the drug, and ANI will be responsible for marketing and distribution in the U.S.
 
The branded product had annual U.S. sales of approximately $1 billion, according to IMS Health. Financial terms were not disclosed.
 
Arthur S. Przybyl, ANI’s president and chief executive officer, said, “I am pleased to have expanded our collaboration with Sofgen through the addition of this second generic drug development project. ANI will continue to invest in both internal R&D efforts as well as external partnerships with high quality partners such as Sofgen.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics